Copyright © 1999 by the European Society of Cardiology.
Prevalence of left ventricular hypertrophy in a general population; The Tromsø Study
a Institute of Community Medicine, University of Tromsø Tromsø Norway
b Institute of Clinical Medicine, University of Tromsø Tromsø Norway
revised August 29, 1998; accepted September 2, 1998
Abstract
Aims
Left ventricular hypertrophy has been shown to be an independent predictor of cardiovascular morbidity. Acknowledging the skewed distribution of left ventricular mass, we wanted to develop criteria for left ventricular hypertrophy based on percentiles of left ventricular mass, and observe the effect on estimates of left ventricular hypertrophyprevalences in different subgroups and on the relationship to cardiovascular risk factors in a general population.
Methods and Results
In a population-based sample of 3287 subjects aged 25–85 years, left ventricular mass was estimated using M-mode echocardiography. A ‘healthy’ subgroup was used as a reference sample to define sex-specific left ventricular hypertrophy criteria. Sex-specific 97·5 percentiles for left ventricular mass by height, based on the reference sample, were 145·5 and 125·4g.m–1, for men and women, respectively. The prevalences of left ventricular hypertrophy in the total population were 14·9% for men and 9·1% for women. The main independent predictors of left ventricular hypertrophy were male gender, body mass index, systolic blood pressure, valvular heart disease, cardiovascular disease and antihypertensive medication. Body mass index and systolic blood pressure had a strong synergistic association with left ventricular hypertrophy in men, but not in women.
Conclusion
An alternative framework for defining left ventricular hypertrophy is provided. Body mass index is the culprit factor for risk of left ventricular hypertrophy. Our study indicates that weight reduction is a relevant measure for treatment and possibly prevention of left ventricular hypertrophy in a substantial part of the general population.
Key Words: Hypertrophy, population, echocardiography, obesity, hypertension, sex
f1 Correspondence: Henrik Schirmer, MD, Institute of Community Medicine, University of Tromsø, 9037 Tromsø, Norway.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M J. S Zaman, J. Sanders, A. M Crook, G. Feder, M. Shipley, A. Timmis, and H. Hemingway Cardiothoracic ratio within the "normal" range independently predicts mortality in patients undergoing coronary angiography Heart, April 1, 2007; 93(4): 491 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dorr, B. Wolff, D. M. Robinson, U. John, J. Ludemann, W. Meng, S. B. Felix, and H. Volzke The Association of Thyroid Function with Cardiac Mass and Left Ventricular Hypertrophy J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 673 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.D. Witham, J.I. Davies, A. Dawson, P.G. Davey, and A.D. Struthers Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations QJM, February 1, 2004; 97(2): 87 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.N Saleh, H Schirmer, J Sundsfjord, and R Jorde Parathyroid hormone and left ventricular hypertrophy Eur. Heart J., November 2, 2003; 24(22): 2054 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Schirmer, P Lunde, and K Rasmussen Mitral flow derived Doppler indices of left ventricular diastolic function in a general population. The Tromso study Eur. Heart J., August 2, 2000; 21(16): 1376 - 1386. [Abstract] [PDF]
|
|
|
|
|
|
E. Edmunds, C.G.C. Spencer, and G.Y.H. Lip Left ventricular hypertrophy in the population. Eur. Heart J., October 1, 1999; 20(20): 1514 - 1515. [PDF]
|
|